Healthcare Jun 23, 2022 10:22 AM (GMT+8) · EqualOcean
Recently, the US FDA psychopharmacology Drug Advisory Committee voted 9:3 against the supplementary new drug application (sdna) of Acadia nuplazid tablets for the treatment of hallucinations and delusions related to Alzheimer's psychosis. The reason for the rejection was that the existing evidence could not support nuplazid's clear efficacy in the treatment of hallucinations and delusions in ADP population.